Axa’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Axa’s Portfolio BIVV Stock Details BIVV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-224,286	Closed	-$12.1M	–	1457
2017 Q4	$12.1M	Sell	224,286 -192	-0.1%	-$10.5K	0.05%	405
2017 Q3	$12.8M	Buy	224,478 +20,191	+10%	+$1.18M	0.06%	374
2017 Q2	$12.3M	Sell	204,287 -6,123	-3%	-$349K	0.06%	373
2017 Q1	$11.5M	Buy	+210,410	New	+$10.4M	0.05%	379

Other funds holding BIVV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ACS

Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

Axa's BIVV Position: Q1 2018 in Review

Axa sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 224,286 shares — an estimated $12.1M sold.

Axa first reported a position in BIVV in Q1 2017 and held it in 4 quarters. The position peaked at $12.8M in Q3 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

Axa reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
Axa sold 224,286 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $12.1M.
Axa first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 4 quarters.
Axa's Bioverativ Inc. Common Stock position peaked at $12.8M in Q3 2017.
2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on Axa's 13F filing for Q1 2018, filed 14 May 2018.